Literature DB >> 15170500

Unexpected elevation of pentosidine formation in collagen incubated with glucose by low concentrations of the AGE-inhibitor aminoguanidine.

P Urios, A-M Grigorova-Borsos, M Sternberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15170500     DOI： 10.1007/s00125-004-1399-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  10 in total

1.  The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid.

Authors:  J F WOESSNER
Journal:  Arch Biochem Biophys       Date:  1961-05       Impact factor: 4.013

2.  Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

Authors:  B I Freedman; J P Wuerth; K Cartwright; R P Bain; S Dippe; K Hershon; A D Mooradian; B S Spinowitz
Journal:  Control Clin Trials       Date:  1999-10

3.  Effects of erythropoietin and aminoguanidine on red blood cell deformability in diabetic azotemic and uremic patients.

Authors:  C D Brown; Z H Zhao; L L Thomas; R deGroof; E A Friedman
Journal:  Am J Kidney Dis       Date:  2001-12       Impact factor: 8.860

4.  Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial.

Authors:  V M Monnier; O Bautista; D Kenny; D R Sell; J Fogarty; W Dahms; P A Cleary; J Lachin; S Genuth
Journal:  Diabetes       Date:  1999-04       Impact factor: 9.461

5.  Chelating activity of advanced glycation end-product inhibitors.

Authors:  D L Price; P M Rhett; S R Thorpe; J W Baynes
Journal:  J Biol Chem       Date:  2001-10-24       Impact factor: 5.157

Review 6.  Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts.

Authors:  Paul J Thornalley
Journal:  Arch Biochem Biophys       Date:  2003-11-01       Impact factor: 4.013

7.  Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose.

Authors:  K J Wells-Knecht; D V Zyzak; J E Litchfield; S R Thorpe; J W Baynes
Journal:  Biochemistry       Date:  1995-03-21       Impact factor: 3.162

8.  Paradoxical impact of antioxidants on post-Amadori glycoxidation: Counterintuitive increase in the yields of pentosidine and Nepsilon-carboxymethyllysine using a novel multifunctional pyridoxamine derivative.

Authors:  Sean M Culbertson; Ekaterina I Vassilenko; Lisa D Morrison; Keith U Ingold
Journal:  J Biol Chem       Date:  2003-07-23       Impact factor: 5.157

9.  Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.

Authors:  R Bucala; Z Makita; G Vega; S Grundy; T Koschinsky; A Cerami; H Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

10.  Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.

Authors:  M Brownlee; H Vlassara; A Kooney; P Ulrich; A Cerami
Journal:  Science       Date:  1986-06-27       Impact factor: 47.728
  10 in total
  1 in total

1.  The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.

Authors:  Joshua I Barzilay; Kathleen A Jablonski; Vivian Fonseca; Steven E Shoelson; Allison B Goldfine; Christopher Strauch; Vincent M Monnier
Journal:  Diabetes Care       Date:  2013-11-19       Impact factor: 19.112
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.